ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for woman's reproductive health and pregnancy. Co.'s portfolio includes: Linzagolix, which is an oral gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis in pre-menopausal women; Ebopiprant, which is an oral selective prostaglandin F2a, receptor antagonist, treatment for preterm labor; and Nolasiban, which improves clinical pregnancy and live birth rates in women undergoing embryo transfer following an in-vitro fertilization cycle. We show 6 historical shares outstanding datapoints in our OBSV shares outstanding history coverage, used to compute OBSV market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing OBSV market cap history over the course of time is important for investors
interested in comparing OBSV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of OBSV versus a peer is one thing; comparing
OBSV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like OBSV can fluctuate over the course of history.
With this page we aim to empower investors researching OBSV by allowing them to research the OBSV market cap history. |
Free OBSV Email Alerts:
Video: The Importance of Market Cap
